Artios Pharma Ltd., the Cambridge, UK-based biotech focusing on the DNA damage response (DDR) to develop first-in-class cancer treatments, has raised £65 million ($83 million) in a series B round led by Andera Partners (formerly EdRIP) and LSP (Life Science Partners) alongside new investors Novartis Venture Fund and Pfizer Ventures and existing shareholders Arix Bioscience, SV Health Investors, M Ventures, IP Group and Abbvie Ventures.
Artios Pharma Hooks Novartis & Pfizer In Over-Subscribed £65M Series B Round
With DNA damage repair pathways attracting a lot of attention as potential targets against various cancers, three-year old Artios Pharma has raised £65 million in an over-subscribed Series B round to fund the clinical development of its pipeline through to 2023.
More from Financing
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.